A method of processing a substrate that includes: depositing first and second monomers over a substrate, the first monomer being a first type of monomer and the second monomer being a second type of monomer different from the first type of monomer; exposing the substrate to a first actinic radiation to induce a polymerization of the first and second monomers over the substrate, where, after the polymerization, the substrate has a bow with a first curvature; and exposing the substrate to a second actinic radiation to induce a rearrangement of the polymer, the rearrangement reducing the bow.
The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+/- PDGFRA+/- EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
3.
CELL-FREE DNA BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF DISEASES WITH DEGENERATIVE PROCESSES
The development of a methylation capture panel that targets methylation sites that vary between tissues at high sequencing depth means that the projected cost for a sample run on the proposed capture technology is 10-fold smaller than with whole genome bisulfite sequencing (WGBS). This unexpected combination of methylation sequencing, cell type identification, machine learning, and capture technology enables a previously unattainable ability to predict disease status. These methods can be used to diagnose, prognose, and stage disease conditions including amyotrophic lateral sclerosis (ALS) and other degenerative conditions. In addition, it offers great advantages for other cfDNA-based detection applications, such as cancer and pregnancy-related conditions.
4.
SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Hol (Ireland)
Inventor
O'Neill, Luke
Coll, Rebecca
Cooper, Matthew
Robertson, Avril
Schroder, Kate
Abstract
The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 37/00 - Drugs for immunological or allergic disorders
C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure relates generally to a composition comprising nucleic acids adsorbed onto layered double hydroxide (LDH) nanoparticles coated in positively-charged protein, and methods of using same to introduce the adsorbed nucleic acids to plants and plant tissues. For example, the LDH nanoparticles of the disclosure may be used to deliver nucleic acids of interest to plants or parts thereof for a range of purposes, including, but not limited to, protecting a plant against pests and diseases, plant trait manipulation, and/or plant gene editing. The present disclosure also relates generally to the use of lysozyme to enhance uptake and internalisation of LDH nanoparticles by plants and plant tissues. For example, the disclosure relates to methods of enhancing uptake and internalisation of LDH nanoparticles by plants and plant tissues by pre-treating the plant or plant tissue with lysozyme prior to incubating the plant or plant tissue with the LDH nanoparticles. The present disclosure also relates to methods for preparing said compositions.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
Disclosed are injectable compositions. Such compositions may be formed from cellulosic fibers and a deep eutectic solvent. Also disclosed are methods of preparing an injectable composition, which comprises: (i) contacting cellulosic fibers with a deep eutectic solvent to provide deep eutectic solvent treated cellulosic fibers; (ii) washing the deep eutectic solvent treated cellulosic fibers; and (iii) homogenizing or mechanically refining the washed deep eutectic solvent treated cellulosic fibers to thereby provide the injectable composition. Also disclosed are uses of the compositions and methods involving the compositions.
C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
7.
A METAL ORGANIC FRAMEWORK (MOF) GLASS COMPOSITE COMPRISING METAL HALIDE PEROVSKITE
The present application relates to a metal organic framework (MOF) glass composite comprising metal halide perovskite, and a method for its preparation.
C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead
A method is provided for simultaneously producing both nephron progenitor cells and ureteric epithelial progenitor cells including the step of contacting intermediate mesoderm cells with: fibroblast growth factor 9 and/or fibroblast growth factor 20 and optionally, one or more selected from the group consisting of: bone morphogenic protein 7; heparin; a Wnt agonist; retinoic acid; and an RA antagonist. The concentrations of Wnt agonist, retinoic acid and/or RA antagonist may be manipulated to favour the relative production of nephron progenitor cells and ureteric epithelial progenitor cells. The intermediate mesoderm cells are ultimately derived from human pluripotent stem cells via a posterior primitive streak stage. The nephron progenitor cells and ureteric epithelial progenitor cells may have end uses such as for kidney repair and regeneration, bioprinting of kidneys and screening compounds for nephrotoxicity.
Disclosed are proteinaceous coagulation factor XIIa (FXIIa) inhibitors and their use for treating or inhibiting the development of a condition in which inhibiting FXIIa stimulates or effects treatment or inhibition of the development of the condition. Suitable conditions include thromboembolism-associated conditions such as acute coronary syndrome, stroke, deep vein thrombosis and pulmonary embolism, a thrombosis, a thrombosis-associated hematologic disorder such as sickle cell disease or thrombophilia, and an inflammatory condition or a condition related to the kallikrein-kinin system such as hereditary angioedema, multiple sclerosis, rheumatoid arthritis or lupus. The proteinaceous FXIIa inhibitors are also useful for treating or inhibiting thrombus and/or embolus formation. In vitro methods for identifying a disulfide rich peptide which binds to a target substance are also disclosed.
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
The present invention relates to cells and methods for studying complex human traits such as diseases and drag responses. The invention relates to cell culture methods involving differentiated cells, in particular from multiple human-induced pluripotent stem cell lines (hiPSC), for population-scale experiments, for example, population genomics of gene regulation.
A phononic circuit component including a membrane coupled to a substrate, the membrane including a region having an array of holes and a channel provided in the substrate beneath the region so that the region is released from the substrate, thereby allowing the region to propagate transverse acoustic waves, wherein the holes are spaced by a distance that is substantially smaller than a wavelength of the acoustic waves.
The present disclosure relates to fluorosurfactants useful for the preparation of emulsions, which may be used in droplet-based microfluidics. The present disclosure also relates to emulsions comprising such surfactants. and methods of preparing such emulsions. The present disclosure further relates to methods and uses of such surfactants and emulsions.
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
C09K 23/00 - Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
13.
DIAGNOSTIC MARKER FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Provided herein are methods for diagnosing functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome, comprising detecting IgG antibodies in a sample obtained from a subject, wherein the IgG antibodies recognise one or more antigens from Streptococcus salivarius. Also provided are kits for detecting IgG antibodies for use in the diagnosis of functional gastrointestinal disorders, and methods for selecting subjects for treatment for functional gastrointestinal disorders.
Disclosed are methods for classifying tumors according to their responsiveness to a therapeutic agent based on the clustering status of a cell surface receptor element to which the therapeutic agent is capable of binding. Also disclosed are 5 methods for stratifying subjects with cancer into treatment subgroups based on this classification as well as methods for treating subjects so stratified.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The present invention relates to a method for determining oxidation of coal, the method comprising: a) mixing a coal sample with an organic solvent and an inorganic solvent, to extract oxidised coal species from the coal sample into a liquid phase, and b) analysing the liquid phase from step (a) to determine a degree of coal oxidation. The inorganic solvent may comprise an inorganic compound such as a pyrophosphate. The present invention also relates to a method for controlling collector used in a coal flotation process, the method comprising determining a degree of oxidation of coal by the preceding method and controlling a ratio of non-polar collector to polar collector in the coal flotation process in response to the determined degree of oxidation of coal.
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
B01D 11/04 - Solvent extraction of solutions which are liquid
TOWNSVILLE HOSPITAL AND HEALTH SERVICE (Australia)
THE STATE OF QUEENSLAND ACTING THROUGH QUEENSLAND HEALTH (Australia)
GRIFFITH UNIVERSITY (Australia)
UNIVERSITY OF QUEENSLAND (Australia)
Inventor
Chavan, Arjun
Hardwick-Greaves, Luke
Atzeni, Damon
Zhang, Patrick
Lovell, Brian
Qiu, Oliver
Liew, Alan
Dicton, Ben
Abstract
Described herein is a system (200) and method (100) of performing automated respirator fit testing. The method (100) includes the initial step (101) of receiving one or more images of a subject's face. Method (100) includes the optional step (102) of receiving biometric information about the subject. At step (103) the one or more images are processed to determine facial features of the subject's face and to output one or more facial feature vectors associated with the facial features. At step (104) the one or more facial feature vectors are input to a machine learning classification module that is trained on a database of stored face images associated with reference fit test data including one or more recommended respirator devices for each face image. At step (105), the machine learning classification module outputs one or more recommended respirator devices for the subject.
A method is disclosed for classifying a target comprising tissue or an extract of tissue as having one or more biomarkers present. A Laser Feedback Interferometer (LFI) is operated with each of an array of THz Quantum Cascade Lasers (QCLs) activated in turn to apply laser radiation at their corresponding predetermined wavelength to the target. Optical responses at each of the predetermined wavelengths are detected by the LFI. Background effect subtraction and scaling is then performed by a processing assembly which classifies the target as having a biomarker present based on the values detected by the LFI at each of the predetermined wavelengths. In the case of the biomarker being DNA extracts that are associated with melanoma then the biomarker is deemed present if reflection amplitude at λ1 is less than reflection amplitude at λ2; and reflection amplitude at λ2 is less than reflection amplitude at λ3. The originating tissue from which the target under test was made can then be appropriately labelled as "biomarker present" or "biomarker absent".
G01N 33/483 - Physical analysis of biological material
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
G01N 21/3581 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation
G01N 21/62 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
18.
AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY
Disclosed are agents, compositions and methods for treating, reducing or inhibiting, or slowing the progression of, unwanted or undesirable immune responses including pro-inflammatory responses. More particularly, the present disclosure relates to a therapeutic agent, therapeutic combinations and their use in compositions and methods for inhibiting or reducing pro-inflammatory activity of immune cells such as antigen-presenting cells (APC), wherein the therapeutic agent comprises D-ribulose-5-phosphate (RL5P), a RL5P analog, a RL5P analog-producing agent and/or a RL5P-producing agent, such as one selected from 6-phosphogluconate dehydrogenase (6PGD) and a nucleic acid molecule from which 6PGD is producible, and wherein the therapeutic combination comprises the therapeutic agent and an HDAC7-producing agent.
A method for detection of a nerve agent in a sample, which method comprises (a) irradiating an optical sensing element, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, and measuring the luminescence of the optical sensing element; wherein the fluorescent sensing compound comprises a combination of at least one electron acceptor moiety and, optionally, one or more electron donor moieties such that the electronic properties of the sensing compound are sufficient to enable a change in the luminescence of the sensing element in the presence of the nerve agent, and a moiety that influences solubility of the sensing compound in a solvent; (b) contacting the sample with the optical sensing element; (c) measuring the luminescence of the optical sensing element; and (d) determining whether the nerve agent is present in the sample based on the measurements obtained in steps (a) and (c).
Mounting apparatus for mounting a turbomachine to a mounting surface, wherein the mounting apparatus includes: a casing that encloses a rotor and a portion of a shaft of the turbomachine in use, the shaft extending in an axial direction, the casing including a plurality of lugs protruding radially from the casing; and a support arrangement including a plurality of support members that are coupled to and extend away from the mounting surface in use, each support member having a coupling end that is coupled to one of the lugs using a thermally insulated coupling in use, and each support member being offset radially from the casing between the coupling end and the mounting surface in use, such that the casing is supported relative to the mounting surface by the support arrangement while substantially preventing heat transfer from the casing to the mounting surface via the support arrangement.
F01K 25/10 - Plants or engines characterised by use of special working fluids, not otherwise provided forPlants operating in closed cycles and not otherwise provided for using special vapours the vapours being cold, e.g. ammonia, carbon dioxide, ether
The present disclosure relates to the field of protein-based inhibitors. More particularly, the present disclosure relates to protein inhibitors for the specific binding of PD-L1 and inhibition of PD-1/PD-L1 signalling. Additionally, this disclosure describes methods of using such protein inhibitors in preventing or treating diseases, disorders or conditions associated with PD-1/PD-L1 signalling.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
An optical path monitoring process, including the following steps executed by a first node of an optical network: (i) generating photons that are at least partially indistinguishable in frequency, polarization, spatial mode and temporal profile; (ii) transmitting a first photon of the generated photons to a remote node of the optical network over an optical path; (iii) receiving the first photon from the remote node over an optical path; and (iv) interfering the received first photon with a second photon of the generated photons to generate a quantum interference visibility output; and (v) assessing physical integrity of the optical path(s) on the basis of the quantum interference visibility output.
G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
H04B 10/07 - Arrangements for monitoring or testing transmission systemsArrangements for fault measurement of transmission systems
H04B 10/071 - Arrangements for monitoring or testing transmission systemsArrangements for fault measurement of transmission systems using a reflected signal, e.g. using optical time domain reflectometers [OTDR]
H04B 10/073 - Arrangements for monitoring or testing transmission systemsArrangements for fault measurement of transmission systems using an out-of-service signal
H04B 10/075 - Arrangements for monitoring or testing transmission systemsArrangements for fault measurement of transmission systems using an in-service signal
H04B 10/11 - Arrangements specific to free-space transmission, i.e. transmission through air or vacuum
H04B 10/25 - Arrangements specific to fibre transmission
A method for detection of a nerve agent in a sample, which method comprises (a) irradiating an optical sensing element, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, and measuring the luminescence of the optical sensing element; wherein the fluorescent sensing compound comprises a combination of at least one electron acceptor moiety and, optionally, one or more electron donor moieties such that the electronic properties of the sensing compound are sufficient to enable a change in the luminescence of the sensing element in the presence of the nerve agent, and a moiety that influences solubility of the sensing compound in a solvent; (b) contacting the sample with the optical sensing element; (c) measuring the luminescence of the optical sensing element; and (d) determining whether the nerve agent is present in the sample based on the measurements obtained in steps (a) and (c).
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for inhibiting Class IIa versus Class I HDACs. The present application also relates to methods of using the compounds and to uses of the compounds, especially in relation to the prevention of a disease, disorder or condition associated with Class IIa HDAC activity. In one form, the compounds are (ortho-phenyl) phenyl hydroxamates. In another form, the compounds are as provided in Formula (I), wherein R1 is a phenyl or cycloalkenyl which may be optionally substituted. Formula (I)
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for inhibiting Class IIa versus Class I HDACs. The present application also relates to methods of using the compounds and to uses of the compounds, especially in relation to the prevention of a disease, disorder or condition associated with Class IIa HDAC activity. In one form, the compounds are (ortho-phenyl) phenyl hydroxamates. In another form, the compounds are as provided in Formula (I), wherein R1 is a phenyl or cycloalkenyl which may be optionally substituted. Formula (I)
The present invention describes a method of distributing one or more of noble metal and inorganic particles throughout a thermoplastic polymer matrix, the method comprising: providing thermoplastic polymer particles having a nucleated shell of noble metal or inorganic material, or a combination of said thermoplastic polymer particles; and melt processing the thermoplastic polymer particles; wherein melt processing of the thermoplastic polymer particles causes the nucleated shell to fragment into particles which become distributed throughout the thermoplastic polymer matrix.
A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
B29B 9/12 - Making granules characterised by structure or composition
This disclosure relates generally to modified SARS-CoV-2 spike polypeptides. More particularly, the present disclosure relates to modified SARS-CoV-2 spike proteins with improved properties, to chimeric polypeptides comprising these modified proteins, and to complexes comprising the chimeric polypeptides. The present disclosure also relates to the use of these modified polypeptides, chimeric polypeptides and complexes in compositions and methods for eliciting an immune response to ACE2-interacting coronaviruses, including SARS-CoV-2, and/or for treating or inhibiting the development of ACE2-interacting coronaviruses infections.
A method and a system for removing a portion of at least one contaminant gas from a gas stream is disclosed. The method comprises the steps of: a) applying a voltage across a pair of electrodes in contact with a working fluid to generate a plurality of ions; and b) reacting the at least one contaminant gas with the plurality of ions to convert it to one or more reaction products, thereby sequestering at least some of the contaminant gas from the first gas stream to produce a second gas stream, wherein the pH of the working fluid is substantially maintained at a predetermined set point for improving the efficiency of the conversion. The invention also relates to a process for treating sewage or wastewater by adding the one or more reaction products to: the sewage, wastewater, sludge and/or an anaerobic digester.
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
The disclosure relates to a method for detecting a nerve agent in an analyte, said nerve agent having a phosphorus-fluorine bond, which method comprises: (a) contacting the analyte with a solid state composition comprising a sensor compound; wherein the sensor compound comprises a basic nitrogen atom and a hydroxyaryl moiety protected by a silyl protecting group; and wherein, in the presence of hydrogen fluoride, said silyl group is cleaved to effect deprotection of the hydroxyl group thus forming a luminescent reporter compound; (b) irradiating the solid state composition at a predetermined wavelength; (c) measuring the luminescence to determine if the reporter compound is present; and (d) determining whether the nerve agent is present in the analyte based on the measurement obtained in step (c).
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
The invention relates to a method of processing graphene comprising the steps of: combining few-layer graphene with a poly(alkylene oxide); drying to form a graphene/poly(alkylene oxide) composite; and calcining the graphene/poly(alkylene oxide) composite thus formed in an inert atmosphere. The invention also relates to processed graphene comprising a few-layer feature, wherein the graphene further comprises one or more features selected from: in-plane nanopores with dimensions of from about 1.5 nm to about 3.5 nm; a greater than 50% expanded interlayer lattice; an expansion interlayer distance of greater than 3.40 Å; and an atomic O/C content of less than 4%. The invention further relates to cathodes and batteries comprising processed graphene, and the use of processed graphene in capacitive deionization or rechargeable battery applications.
The present invention relates to a biocompatible implantable scaffold comprising a first scaffold portion comprising a first array of spaced walls having a first height, wherein the walls of the first array of spaced walls are connected by one or more transverse connectors, and are substantially impermeable to cell transport and/or growth therethrough, and are spaced apart from each other by a predetermined distance to promote cell growth and orientation substantially aligned with the first height of the walls of the first array of spaced walls. Further provided is a method of making the biocompatible implantable scaffold of the invention, and methods of treating and/or repairing a periodontal defect in a subject in need thereof, comprising implanting a biocompatible implantable scaffold of the invention into the periodontium of said subject.
A61C 8/02 - Means for transfixation of natural teeth
A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The disclosure relates to a substituted cyclooctatetraene triplet excited-state quencher compound of Formula (I): wherein: Z is a wide band gap moiety; L is a non-conjugating linker group; each R, which may be the same or different, is a non-conjugating substituent; n is an integer from 0 to 7; and m is an integer from 1 to 6. The disclosure further relates to use of such compounds as triplet quenchers, compositions comprising such compounds, films or coatings comprising said compounds or compositions, and use of said compositions or films or coatings as active gain media for light amplification.
H10K 85/60 - Organic compounds having low molecular weight
C07D 209/86 - CarbazolesHydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
32.
PEPTIDES AND USES THEREOF IN MODULATION OF AMYLOID-BETA PROTEIN DEGRADING PROTEASES
Described herein are peptides of formula (I) and pharmaceutical compositions and kits comprising the peptides. The use of the peptides in methods of treating or preventing diseases that are associated with modulation of Amyloid-beta protein-degrading proteases, such as neprilysin and angiotensin-converting enzyme 2, are also described.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 63/331 - Polycyclic acids with all carboxyl groups bound to non-condensed rings
C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
34.
USES OF JAK INHIBITORS IN THE MANAGEMENT OF INFLAMMATION-ASSOCIATED DEPRESSION AND CENTRAL NERVOUS SYSTEM (CNS) PATHOLOGIES
This disclosure relates to methods of treating, preventing, or reversing inflammation-associated central nervous system (CNS) disorders or conditions comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the CNS associated inflammatory disorder is depression, treatment resistant depression, fatigue, or cognitive dysfunction.
A method for treating bauxite residue contained in a storage facility comprising adding a mixture containing (a) a source of organic carbon, (b) a source of phosphorous or a source of phosphate, (c) a source of calcium, and a source of sulphur or sulphate to the bauxite residue, to thereby promote growth of microbes well adapted to highly saline and alkaline habitat, or to promote growth of marine microbes, or to promote growth of tolerant and marine origin haloalkaliphilic bacteria, or to promote growth of haloalkaliphilic organotrophic bacteria, preferably of marine origin. The method may comprise adding plant material or mulch and superphosphate fertilisers to the bauxite residue.
C05F 17/20 - Preparation of fertilisers characterised by biological or biochemical treatment steps, e.g. composting or fermentation using specific microorganisms or substances, e.g. enzymes, for activating or stimulating the treatment
The invention relates to Clec9A, to antigen binding proteins and related fragments thereof for binding to Clec9A, to production of said antigen binding proteins and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular inflammation, infection and oncology.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
This invention relates to a method of producing a circularised form of a target protein from a fusion protein and to a fusion protein capable of producing a circularised form of a target protein. The fusion protein can comprise: the target protein; at least one circularisation site adjacent the target protein; and an enzyme domain capable of interacting with the at least one circularisation site and circularising the target protein. The target protein can be a membrane scaffold protein or a cyclotide such as SFTI, Vc1.1, Kalata B1 or MCOTI-II.
This invention relates to, in some aspects, a method of preparing a gel-based composition or a thermo-responsive sol-gel composition, including the steps of: (a) providing a mixture of a first aqueous solution comprising a first poloxamer and/or a first poloxamine with a solvent solution comprising a water miscible solvent and a hydrophobic therapeutic agent, wherein the water miscible solvent has a boiling point of less than 105° C. at atmospheric pressure and wherein the first aqueous solution and/or the solvent solution further comprise a surfactant; (b) substantially removing the water miscible solvent and water from the mixture in (a) to produce a micelle composition; and (c) contacting the micelle composition with a second aqueous solution comprising a second poloxamer and/or a second poloxamine to thereby prepare the thermo-responsive sol-gel composition. In other aspects, the present invention relates to a method of preparing a micelle composition, a thermo-responsive sol-gel composition or a gel-based composition for therapeutic use, and to methods of using the compositions.
B01J 13/12 - Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present disclosure relates generally to chimeric polypeptides that comprise a microbial polypeptide (preferably (a) a virion surfaced exposed portion of an enveloped viral fusion protein or (b) a bacterial outer membrane polypeptide) and a heterologous structure-stabilizing moiety, and to complexes comprising those chimeric polypeptides. The present disclosure also relates to the use of these chimeric polypeptides and complexes thereof in compositions and methods for eliciting an immune response to a microbial polypeptide (preferably a fusion protein of an enveloped virus or a bacterial outer membrane polypeptide), or to respective complexes thereof and/or for treating or preventing related microbial infection (preferably an enveloped virus infection or a bacterial infection). Moreover, the disclosure further relates to compositions and methods for producing an antigen-binding molecule that specifically binds to such a microbial polypeptide or a complex thereof (preferably to an enveloped viral fusion protein or a complex thereof, or to a bacterial outer membrane polypeptide or a complex thereof).
C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
C07K 14/465 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from birds
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
in vivoin vivoin vivo, and recombinant cells that comprise amplified genes. The methods of increasing gene copy number involve reducing expression levels of a haploinsufficient gene in the genome of recombinant cells, such as through replacing the endogenous promoter with a weaker promoter.
A fault detection assembly for a PV solar generation assembly comprised of an array of PV modules including a plurality of series PV module strings connected in parallel, the fault detection assembly including: a plurality of current sensors arranged to monitor respective string currents of said strings; a processing arrangement in communication with the current sensors for receiving values of the string currents therefrom; a memory device accessible to the processing arrangement containing instructions for execution by the processing arrangement including instructions for: determining a representative string current for currents of the plurality of strings; deeming one or more strings having currents that are outliers to the representative string current by more than a threshold value to be subject to a fault; and issuing an alarm including an identification of the one or more strings deemed to be subject to the fault.
A multi-modal antenna for use in magnetic resonance applications, the multi-modal antenna including an elongate first conductive element, an elongate second conductive element at least partially aligned with and spaced from the first conductive element and a dielectric material at least partially separating the first and second conducting elements so that the first and second conductive elements are electromagnetically coupled and/or electrically connected, and wherein at least one of the first and second conducting elements are configured to be electromagnetically coupled and/or electrically connected to an RF system so that the multi-modal antenna can at least one of transmit and receive RF electromagnetic signals for performing magnetic resonance imaging or spectroscopy.
H01Q 9/26 - Resonant antennas with feed intermediate between the extremities of the antenna, e.g. centre-fed dipole with folded element or elements, the folded parts being spaced apart a small fraction of operating wavelength
H01Q 21/06 - Arrays of individually energised antenna units similarly polarised and spaced apart
H01Q 21/20 - Arrays of individually energised antenna units similarly polarised and spaced apart the units being spaced along, or adjacent to, a curvilinear path
A spatial encoding arrangement forming part of a low field magnetic resonance imaging system for generating a spatially encoded measurement field for use in a low field magnetic resonance imaging process, the low field magnetic resonance imaging system including a pre-polarisation magnet arrangement for generating a pre-polarisation field in a field-of-view and a measurement magnet arrangement for generating a measurement field in the field-of-view, the spatial encoding arrangement including at least one magnetic encoding element movable relative to the field-of-view to thereby spatially encode the measurement field for each of a plurality of readings.
A rating generator assembly 30 is configured to perform a method to associate quality ratings with each digital resource, such as a learning resource, of a plurality of learning resources, e.g. resources 5-1, . . . ,5-M, (QM={q1 . . . qM} in respect of a topic of an educational course. The method comprises, in respect of each of the learning resources, receiving one or more indications of quality, for example in the form of decision ratings dij and comments cij, in respect of the learning resource q1 from respective devices (“non-expert devices” e.g. 3a, . . . ,3N) of a plurality of non-experts, for example students (UN={u1, . . . , UN}) 3-1, . . . ,3-N via a data network 31. The method involves operating at least one processor, of the rating generator assembly 30 to process the one or more indications of quality from each of the respective non-expert devices 3a, . . . ,3N to determine a draft quality rating {circumflex over (r)}i and an associated level of confidence or “confidence value” of that draft quality rating. The method includes repeatedly receiving indications of quality from further of the non-expert devices and updating the draft quality rating and its associated level of confidence until the associated level of confidence meets a required confidence level. Once the required confidence level has been met the rating generator assembly sets the quality rating to the draft quality rating having the associated level of confidence meeting the required confidence level.
The present invention relates to the use of a population of cells into which an engineered barcode unique to the cells has been stably integrated and the use of such cells in combination with one or more other populations of cells into which an engineered barcode unique to each other population which has been stably integrated for multiplexed analysis.
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
46.
METHOD OF CALCULATING IN VIVO FORCE ON AN ANTERIOR CRUCIATE LIGAMENT
A method of calculating in vivo force on an anterior cruciate ligament (ACL) by measuring one or more biomechanical properties during a biomechanical screening task to obtain one or more biomechanical datum from the measured one or more biomechanical properties, and calculating a total load on an anterior cruciate ligament from an ACL force model using the one or more biomechanical datum as inputs to the ACL force model. The ACL force model is defined by FACL=FACLsag+FACLfront+FACLtrans+ΣjCTj, wherein FACL is the total force on the ACL, FACLsag is the force on the ACL in a sagittal plane, FACLfront is the force on the ACL in the frontal plane, FACLtrans is the force on the ACL in the transverse plane, and CTj is the ACL force interaction relationships among the sagittal-frontal (SF), sagittal-transverse (ST), and frontal-transverse (FT) planes, where j=SF, ST, FT.
A61B 5/313 - Input circuits therefor specially adapted for particular uses for electromyography [EMG]
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A method for stabilising a froth or a foam comprising subjecting the froth or foam to vibrations or sound waves having a frequency of less than 20 kHz. The frequency may be less than 1 kHz, for example, a frequency of from 300 Hz to 500 Hz, or from 300 to 450 Hz, or from 300 to 400 Hz. A method for froth flotation is also described.
Disclosed herein is a composition for additive manufacturing, said composition comprising Ti-6A1-4V particles, Ti particles, and a beta stabiliser. Also disclosed herein is a method for additive manufacturing, in particular for metallic additive manufacturing, using the composition; a method for producing the composition; and alloys and printed parts produced from the composition.
Disclosed are proteinaceous coagulation factor XIIa (FXIIa) inhibitors and their use for treating or inhibiting the development of a condition in which inhibiting FXIIa stimulates or effects treatment or inhibition of the development of the condition. Suitable conditions include thromboembolism-associated conditions such as acute coronary syndrome, stroke, deep vein thrombosis and pulmonary embolism, a thrombosis, a thrombosis-associated hematologic disorder such as sickle cell disease or thrombophilia, and an inflammatory condition or a condition related to the kallikrein-kinin system such as hereditary angioedema, multiple sclerosis, rheumatoid arthritis or lupus. The proteinaceous FXIIa inhibitors are also useful for treating or inhibiting thrombus and/or embolus formation. In vitro methods for identifying a disulfide rich peptide which binds to a target substance are also disclosed.
C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
Disclosed are proteinaceous complement factor C5a receptor agonists, and their use for treating or inhibiting the development of a condition in which enhancing C5a receptor activity stimulates or effects treatment or inhibition of the development of the condition, such as a cancer, an infection, an inflammatory disorder or a central nervous system trauma (such as a spinal cord injury), as well as for eliciting or enhancing an immune response, regenerating tissue and mobilising cells.
Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 63/331 - Polycyclic acids with all carboxyl groups bound to non-condensed rings
C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
HORTICULTURE INNOVATION AUSTRALIA LIMITED (Australia)
COTTON RESEARCH AND DEVELOPMENT CORPORATION (Australia)
Inventor
Mitter, Neena
Jain, Ritesh Gyanchandaji
Fletcher, Stephen John
Panayi, Aris
Murphy, Kieran
Abstract
The present disclosure provides methods and compositions to control pests that cause damage to crop plants, for example, to control whitefly. The methods and compositions disclosed employ one or more silencing elements that decrease the level of one or more target sequences in the pest.
A01N 25/22 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients stabilising the active ingredients
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
This invention relates to an immunogenic agent comprising a hydrophobic peptide covalently coupled or conjugated to at least one antigenic molecule that facilitates self-assembly of a plurality of the immunogenic agents into an immunogenic complex that has adjuvant properties. The invention also relates to a method of eliciting an immune response in a subject, comprising the step of administering to the subject at least one immunogenic agent or at least one immunogenic complex to thereby elicit an immune response in the subject.
An apparatus (40) for deaerating a froth comprising a spinning basket (44) mounted on a driven shaft (46). The side walls of the spinning basket have a mesh or openings therein. Froth is supplied to the interior of the spinning basket and contacts the floor of the spinning basket and is flung outwardly through the mesh or openings to break the bubbles and deaerate the froth. A solid all (42) may surround the spinning basket to further assist in deaeration. A spinning plate may be used in place of the spinning basket. In another embodiment, vacuum is used to deaerate the froth.
Disclosed are injectable compositions. Such compositions may be formed from cellulosic fibers and a deep eutectic solvent. Also disclosed are methods of preparing an injectable composition, which comprises: (i) contacting cellulosic fibers with a deep eutectic solvent to provide deep eutectic solvent treated cellulosic fibers; (ii) washing the deep eutectic solvent treated cellulosic fibers; and (iii) homogenizing or mechanically refining the washed deep eutectic solvent treated cellulosic fibers to thereby provide the injectable composition. Also disclosed are uses of the compositions and methods involving the compositions.
A61L 27/58 - Materials at least partially resorbable by the body
C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
Disclosed are injectable compositions. Such compositions may be formed from cellulosic fibers and a deep eutectic solvent. Also disclosed are methods of preparing an injectable composition, which comprises: (i) contacting cellulosic fibers with a deep eutectic solvent to provide deep eutectic solvent treated cellulosic fibers; (ii) washing the deep eutectic solvent treated cellulosic fibers; and (iii) homogenizing or mechanically refining the washed deep eutectic solvent treated cellulosic fibers to thereby provide the injectable composition. Also disclosed are uses of the compositions and methods involving the compositions.
A61L 27/58 - Materials at least partially resorbable by the body
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
57.
A METAL ORGANIC FRAMEWORK (MOF) GLASS COMPOSITE COMPRISING METAL HALIDE PEROVSKITE
The present application relates to a metal organic framework (MOF) glass composite comprising metal halide perovskite, and a method for its preparation.
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
H01L 31/0256 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by the material
H01L 31/04 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices
H01L 31/09 - Devices sensitive to infrared, visible or ultra- violet radiation
H01L 31/20 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof such devices or parts thereof comprising amorphous semiconductor material
H01L 33/16 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous
H01L 51/56 - Processes or apparatus specially adapted for the manufacture or treatment of such devices or of parts thereof
58.
APPARATUS AND METHOD FOR FORMING EMULSIONS FOR USE IN FLOTATION
An apparatus for forming an emulsion comprising an aqueous phase and a hydrophobic phase comprising diesel or an oily component or a non-water soluble component, the apparatus comprising a venturi mixer (32) and a static mixer (44) in series.
The present invention relates to an optical sensing element for detection of a narcotic, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, wherein emission of the fluorescent sensing compound is quenched in the presence of the narcotic, and wherein the fluorescent sensing compound is non-polymeric and comprises an electron donor moiety, an electron acceptor moiety and a moiety that influences solubility of the compound in a solvent. Sensing devices incorporating the sensing element and methods of detecting narcotics are also described.
The present invention relates to antigen binding sites, compositions and uses thereof in the treatment of conditions associated with pathogenic proteins. In one example the condition is Alzheimer's disease.
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
An apparatus (20) for monitoring flotation performance apparatus comprises an arm (21) having a paddle (22) attached at one end. The apparatus (20) forms a sensor to monitor real-time flotation performance by measuring the drag exerted by the overflowing froth onto a cantilever beam arm. The strain exerted on the beam or arm can be directly correlated to the efficiency of the froth flotation process. Methods for monitoring and controlling a froth flotation process and a method to determine ash content in coal undergoing flotation are also described
G01L 5/00 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes
G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
G01N 11/14 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
62.
DIAGNOSTIC MARKER FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Provided herein are methods for diagnosing functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome, comprising detecting IgG antibodies in a sample obtained from a subject, wherein the IgG antibodies recognise one or more antigens from Streptococcus salivarius. Also provided are kits for detecting IgG antibodies for use in the diagnosis of functional gastrointestinal disorders, and methods for selecting subjects for treatment for functional gastrointestinal disorders.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australia)
THE SCRIPPS RESEARCH INSTITUTE (USA)
THE UNIVERSITY OF QUEENSLAND (Australia)
Inventor
Puttick, Simon
Kryza, Thomas
Hooper, John
He, Yaowu
Harrington, Brittney
Quigley, James
Deryugina, Elena
Abstract
The present disclosure relates to anti-CDCP1 antibodies, and antigen binding fragments thereof that specifically bind to the full length and cleaved forms CUB domain-containing protein 1 (CDCP1), and conjugates comprising anti-CDCP1 antibodies and uses thereof for treatment and detection of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
64.
Composition, particulate materials and methods for making particulate materials
Particulate material comprising rough mesoporous hollow nanoparticles. The rough mesoporous hollow nanoparticles may comprise a mesoporous shell, the external surface of which has projections thereon, the projections having smaller sizes than the particle size. The particulate material may be used to deliver active agents, such as insecticides and pesticides. The active agents can enter into the hollow core of the particles and be protected from degradation by sunlight. The rough surface of the particles retains the particles on plant leaves or animal hair. Methods for forming the particles are also described. Carbon particles and methods for forming carbon particles are also described.
B01J 13/18 - In situ polymerisation with all reactants being present in the same phase
B01J 13/20 - After-treatment of capsule walls, e.g. hardening
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Germany)
THE UNIVERSITY OF QUEENSLAND (Australia)
Inventor
Kragler, Friedrich
Kadam, Ulhas
Carroll, Bernard John
Abstract
The present invention relates to the field of gene silencing. The present invention inter alia concerns circular RNAs, compositions and kits comprising circular RNAs, methods of producing circular RNAs, methods of inhibiting the expression of a target gene or the function of a target gene in a cell, and uses of circular RNAs and compositions comprising circular RNAs.
The present invention relates to a method for determining oxidation of coal, the method comprising: a) mixing a coal sample with an organic solvent and an inorganic solvent, to extract oxidised coal species from the coal sample into a liquid phase, and b) analysing the liquid phase from step (a) to determine a degree of coal oxidation. The inorganic solvent may comprise an inorganic compound such as a pyrophosphate. The present invention also relates to a method for controlling collector used in a coal flotation process, the method comprising determining a degree of oxidation of coal by the preceding method and controlling a ratio of non-polar collector to polar collector in the coal flotation process in response to the determined degree of oxidation of coal.
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
The present invention relates to a method for determining oxidation of coal, the method comprising: a) mixing a coal sample with an organic solvent and an inorganic solvent, to extract oxidised coal species from the coal sample into a liquid phase, and b) analysing the liquid phase from step (a) to determine a degree of coal oxidation. The inorganic solvent may comprise an inorganic compound such as a pyrophosphate. The present invention also relates to a method for controlling collector used in a coal flotation process, the method comprising determining a degree of oxidation of coal by the preceding method and controlling a ratio of non-polar collector to polar collector in the coal flotation process in response to the determined degree of oxidation of coal.
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
A method for producing nano-clays comprising forming a mixture of a clay and water, wherein water is present in an amount of from 2 to 10% by weight of the total weight of clay and water, and milling the mixture of clay and water in the presence of a grinding media to form the nano-clay.
The present invention relates, inter alia, to a method for stabilising PVC comprising contacting the PVC with one or more chemicals or reactants that result in removal of chlorine from the PVC so that chlorine is removed from the PVC to thereby stabilise the PVC. The PVC may comprise PVC fibres, and the PVC stabilised by the method may be used to form carbon fibres. Accordingly, the present invention also relates to a method for producing carbon fibres from PVC comprising the steps of dissolving PVC into a solvent, mixing the solution of the solvent and dissolved PVC with an anti-solvent to form fibres of PVC, chemically stabilising the PVC fibres and converting the chemically stabilised PVC fibres to carbon fibres.
C08J 11/04 - Recovery or working-up of waste materials of polymers
D01F 6/10 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of halogenated hydrocarbons from polyvinyl chloride or polyvinylidene chloride
D01F 9/21 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from polyaddition, polycondensation or polymerisation products from macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
C08F 8/26 - Removing halogen atoms or halogen-containing groups from the molecule
The present invention relates, inter alia, to a method of producing a co-precipitate comprising nickel, manganese and/or cobalt, and to a co-precipitate produced by the method. The method may be a method of producing a co-precipitate comprising at least two metals selected from nickel, cobalt and manganese, and comprise: (i) providing an aqueous feed solution comprising said at least two metals and at least one impurity; and (ii) adjusting the pH of the feed solution to between about 6.2 and about 11, so as to provide: (a) a co-precipitate comprising said at least two metals; and (b) a supernatant comprising said at least one impurity.
A method for stratifying severity of asthma of a patient initially comprises receiving acoustic data corresponding to sounds of the patient from an acoustic sensor and identifying, by a processor, at least one cough sound in the acoustic data. With or without the patient being present, the method further involves determining, by operation of the processor, one or more overall cough sound feature values of the at least one cough sound for each of one or more characteristic features. The overall cough sound feature values are then applied to a classifier that is implemented by the processor and which has been pre-trained with a training set of characteristic feature values from a population of asthmatic and non-asthmatic subjects. The method then involves monitoring an output from the pre-trained classifier to deem the patient cough sound as indicating one of a number of degrees of severity of asthma.
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A microwave circulator including an integrated circuit and having a number of ports, a respective superconducting ring segment coupled to each port to allow microwave frequency signals to be transferred between the port and the respective ring segment, a superconducting tunnel junction interconnecting each pair of adjacent ring segments to form a circulator ring, wherein the tunnel junctions are configured so that when a bias is applied to the tunnel junctions, signals undergo a phase shift as they traverse the tunnel junctions between ring segments, thereby propagating signals to an adjacent port in a propagation direction and at least one feature to at least partially suppress quasiparticles within the circulator.
H01L 39/02 - Devices using superconductivity or hyperconductivity; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details
H01L 39/08 - Devices using superconductivity or hyperconductivity; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details characterised by the shape of the element
H01L 39/12 - Devices using superconductivity or hyperconductivity; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details characterised by the material
A phononic circuit component including a membrane coupled to a substrate, the membrane including a region having an array of holes and a channel provided in the substrate beneath the region so that the region is released from the substrate, thereby allowing the region to propagate transverse acoustic waves, wherein the holes are spaced by a distance that is substantially smaller than a wavelength of the acoustic waves.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australia)
THE UNIVERSITY OF QUEENSLAND (Australia)
Inventor
White, Alison Louise
Biggs, Simon Richard
Javier, Hazel Anne
Abstract
The present disclosure relates to electroless plating process for preparing microcapsules comprising an ionic shell encapsulating a fluid core. Platinum nanoparticles are used as the catalyst for the electroless plating process and are found in the fluid core. The ionic shell is comprised of inorganic salts, such as salts of alkaline earth metals. In particular electroless plating of calcium phosphate shell on to fluid cores, polymer encapsulated fluid cores and gel cores are disclosed.
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for inhibiting Class IIa versus Class I HDACs. The present application also relates to methods of using the compounds and to uses of the compounds, especially in relation to the prevention of a disease, disorder or condition associated with Class IIa HDAC activity. In one form, the compounds are (ortho-phenyl) phenyl hydroxamates. In another form, the compounds are as provided in Formula (I), wherein R1 is a phenyl or cycloalkenyl which may be optionally substituted. Formula (I)
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07C 275/28 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/46 - Iso-indolesHydrogenated iso-indoles with an oxygen atom in position 1
C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 215/40 - Nitrogen atoms attached in position 8
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 233/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 235/08 - Radicals containing only hydrogen and carbon atoms
C07D 239/36 - One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
C07D 243/08 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
A method for treating wastewater or sludge comprises the steps of adding the wastewater or sludge to a reactor and mixing the wastewater or sludge with a stream to thereby decrease a ratio of alkalinity to ammonium in the reactor, the reactor containing ammonium oxidising bacteria that oxidise ammonium to produce nitrite and decrease pH.
The present invention relates to a peptide for treating an inflammatory or autoimmune condition, pharmaceutical compositions comprising same, and methods of use comprising same.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 35/62 - LeechesWorms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
This invention relates to compositions and uses of genome edited iPSCs and cells derived therefrom. In particular the iPSCs and cells derived therefrom and compositions comprising the same according to the present invention may be used in cell-based therapies for tissue repair or regeneration. The invention relates to the treatment and/or prevention of injury to the myocardium, and/or ischemia reperfusion injury in the myocardium and other vascularized tissues.
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
79.
COMPOUND, ORGANIC SEMICONDUCTOR LASER AND METHOD FOR PRODUCING SAME
A compound of the formula (1) exhibits high photoluminescence quantum yields, high radiative decay constant and low ASE thresholds from solution-processed neat and blend films. Ar1 and Ar2 are aryl groups, L is a divalent group having a group of the formula (2), and R is H or a diarylamino group. At least one alkyl group having at least five carbon atoms which are bonded is present in the formula (1).
A compound of the formula (1) exhibits high photoluminescence quantum yields, high radiative decay constant and low ASE thresholds from solution-processed neat and blend films. Ar1 and Ar2 are aryl groups, L is a divalent group having a group of the formula (2), and R is H or a diarylamino group. At least one alkyl group having at least five carbon atoms which are bonded is present in the formula (1).
C07D 209/86 - CarbazolesHydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
H01S 5/36 - Structure or shape of the active regionMaterials used for the active region comprising organic materials
H01S 5/12 - Construction or shape of the optical resonator the resonator having a periodic structure, e.g. in distributed feedback [DFB] lasers
The invention relates to a method of processing graphene comprising the steps of: combining few-layer graphene with a poly(alkylene oxide); drying to form a graphene/poly(alkylene oxide) composite; and calcining the graphene/poly(alkylene oxide) composite thus formed in an inert atmosphere. The invention also relates to processed graphene comprising a few-layer feature, wherein the graphene further comprises one or more features selected from: in-plane nanopores with dimensions of from about 1.5 nm to about 3.5 nm; a greater than 50% expanded interlayer lattice; an expansion interlayer distance of greater than 3.40 Å; and an atomic O/C content of less than 4 %. The invention further relates to cathodes and batteries comprising processed graphene, and the use of processed graphene in capacitive deionization or rechargeable battery applications.
Described herein are peptides of formula (I) and pharmaceutical compositions and kits comprising the peptides. The use of the peptides in methods of treating or preventing diseases that are associated with modulation of Amyloid-beta protein-degrading proteases, such as neprilysin and angiotensin-converting enzyme 2, are also described.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention relates to a method of processing graphene comprising the steps of: combining few-layer graphene with a poly(alkylene oxide); drying to form a graphene/poly(alkylene oxide) composite; and calcining the graphene/poly(alkylene oxide) composite thus formed in an inert atmosphere. The invention also relates to processed graphene comprising a few-layer feature, wherein the graphene further comprises one or more features selected from: in-plane nanopores with dimensions of from about 1.5 nm to about 3.5 nm; a greater than 50% expanded interlayer lattice; an expansion interlayer distance of greater than 3.40 Å; and an atomic O/C content of less than 4 %. The invention further relates to cathodes and batteries comprising processed graphene, and the use of processed graphene in capacitive deionization or rechargeable battery applications.
UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE UNIVERSITY OF QUEENSLAND (Australia)
Inventor
O'Keefe, Barry R.
Haugh Krumpe, Lauren R.
Pommier, Yves
Marchand, Christophe R.
Schroeder, Ingrid C.
Rosengren, K. Johan
Wilson, Brice A.P.
Abstract
Disclosed is a class of knotted cyclic peptides. Related pharmaceutical compositions and methods of using the peptides and methods of synthesizing the peptides are also disclosed.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The disclosure relates to a method for detecting a nerve agent in an analyte, said nerve agent having a phosphorus-fluorine bond, which method comprises: (a) contacting the analyte with a solid state composition comprising a sensor compound; wherein the sensor compound comprises a basic nitrogen atom and a hydroxyaryl moiety protected by a silyl protecting group; and wherein, in the presence of hydrogen fluoride, said silyl group is cleaved to effect deprotection of the hydroxyl group thus forming a luminescent reporter compound; (b) irradiating the solid state composition at a predetermined wavelength; (c) measuring the luminescence to determine if the reporter compound is present; and (d) determining whether the nerve agent is present in the analyte based on the measurement obtained in step (c).
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE UNIVERSITY OF QUEENSLAND (Australia)
Inventor
O'Keefe, Barry R.
Haugh Krumpe, Lauren R.
Pommier, Yves
Marchand, Christophe R.
Schroeder, Ingrid C.
Rosengren, K. Johan
Wilson, Brice A.P.
Abstract
Disclosed is a class of knotted cyclic peptides. Related pharmaceutical compositions and methods of using the peptides and methods of synthesizing the peptides are also disclosed.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A method for treating bauxite residue contained in a storage facility comprising adding a mixture containing (a) a source of organic carbon, (b) a source of phosphorous or a source of phosphate, (c) a source of calcium, and a source of sulphur or sulphate to the bauxite residue, to thereby promote growth of microbes well adapted to highly saline and alkaline habitat, or to promote growth of marine microbes, or to promote growth of tolerant and marine origin haloalkaliphilic bacteria, or to promote growth of haloalkaliphilic organotrophic bacteria, preferably of marine origin. The method may comprise adding plant material or mulch and superphosphate fertilisers to the bauxite residue.
A62D 3/02 - Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances by biological methods, i.e. processes using enzymes or microorganisms
A method for treating bauxite residue contained in a storage facility comprising adding a mixture containing (a) a source of organic carbon, (b) a source of phosphorous or a source of phosphate, (c) a source of calcium, and a source of sulphur or sulphate to the bauxite residue, to thereby promote growth of microbes well adapted to highly saline and alkaline habitat, or to promote growth of marine microbes, or to promote growth of tolerant and marine origin haloalkaliphilic bacteria, or to promote growth of haloalkaliphilic organotrophic bacteria, preferably of marine origin. The method may comprise adding plant material or mulch and superphosphate fertilisers to the bauxite residue.
A62D 3/02 - Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances by biological methods, i.e. processes using enzymes or microorganisms
88.
Quantum dots and processes for preparation thereof
Disclosed are processes for preparing hybrid perovskite quantum dots and the resulting hybrid perovskite quantum dots and uses thereof. Such quantum dots are useful as semiconductors in devices such as solar cells and light-emitting diodes.
C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 40/00 - Manufacture or treatment of nanostructures
H01L 31/0352 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions
The present invention relates to methods of restoring cognitive function in aged individuals that do not exhibit a clinically detectable neurodegenerative disease. In one aspect, the present invention provides a method of improving cognitive function in an aged individual that does not have a neurodegenerative disease characterized by aggregation of a pathological protein, the method comprising or consisting of: applying a clinically safe level of acoustic energy to sites within a region of the brain, thereby saturating or substantially saturating the region with acoustic energy, thereby improving cognitive function in the aged individual.
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australia)
UNIVERSITY OF QUEENSLAND (Australia)
Inventor
White, Alison Louise
Abstract
The present disclosure generally relates to microcapsules, processes for preparing microcapsules, and applications for the microcapsules. The present disclosure also relates to microcapsules comprising an ionic shell encapsulating a fluid core, the fluid core comprising metal ions. The present disclosure also relates to processes for preparing microcapsules comprising an ionic shell encapsulating a fluid core, the fluid core comprising metal ions.
Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure-stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
The present invention describes a method of capturing a fluorinated carbon compound located within a liquid, the method comprising contacting the fluorinated carbon compound with a block copolymer having a backbone comprising a hydrophilic block and a fluoropolyether block, wherein the fluorinated carbon compound binds to and is captured by the block copolymer.
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
C02F 1/28 - Treatment of water, waste water, or sewage by sorption
C02F 1/58 - Treatment of water, waste water, or sewage by removing specified dissolved compounds
C08F 290/00 - Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
COTTON RESEARCH AND DEVELOPMENT CORPORATION (Australia)
Inventor
Pirie, Rhys
Batstone, Damien
Abstract
A method for the alkaline digestion of soda-lime glass comprising forming a mixture of soda lime glass and a hydroxide solution, the mixture having at least 100 grams of glass per litre of H2O, the hydroxide solution having a concentration of 1M or greater to thereby form an aqueous sodium silicate fraction having a silicate concentration of 50 g/L or greater (calculated as SiO2 equivalent) and a ratio of SiO2:M2O of at least 1, wherein M2O is an alkaline metal oxide, by digesting the glass in the mixture; and separating the aqueous sodium silicate fraction from solids. The solids contain calcium silicate hydrate and undissolved glass. The calcium silicate hydrate can be CSH treated with an acid to thereby dissolve soluble metals from the CSH and separating a liquid phase from a solid phase, the solid phase comprising SiO2 or silica gel.
The invention relates to Clec9A, to antigen binding proteins and related fragments thereof for binding to Clec9A, to production of said antigen binding proteins and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular inflammation, infection and oncology.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The disclosure relates to a substituted cyclooctatetraene triplet excited-state quencher compound of Formula (I): wherein: Z is a wide band gap moiety; L is a non-conjugating linker group; each R, which may be the same or different, is a non- conjugating substituent; n is an integer from 0 to 7; and m is an integer from 1 to 6. The disclosure further relates to use of such compounds as triplet quenchers, compositions comprising such compounds, films or coatings comprising said compounds or compositions, and use of said compositions or films or coatings as active gain media for light amplification.
C07D 209/86 - CarbazolesHydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
C07C 13/567 - FluorenesCompletely or partially hydrogenated fluorenes
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
H01S 3/09 - Processes or apparatus for excitation, e.g. pumping
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (Ireland)
Inventor
O'Neill, Luke
Coll, Rebecca
Cooper, Matthew
Robertson, Avril
Schroder, Kate
Abstract
The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 5/00 - Drugs for disorders of the endocrine system
C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
The present technology is directed to fluorophore-containing compounds useful in the imaging of peripheral neurons as well as to proteins useful in the treatment (including management) of pain.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A rating generator assembly 30 is configured to perform a method to associate quality ratings with each digital resource, such as a learning resource, of a plurality of learning resources, e.g. resources 5-1,?,5-M, (QM = {q1 ...qM} ) in respect of a topic of an educational course. The method comprises, in respect of each of the learning resources, receiving one or more indications of quality, for example in the form of decision ratings dij and comments cij, in respect of the learning resource q1 from respective devices ("non-expert devices" e.g. 3a,..,3N) of a plurality of non-experts, for example students (UN = {u1,?,uN}) 3-1,..,3-N via a data network 31. The method involves operating at least one processor, of the rating generator assembly 30 to process the one or more indications of quality from each of the respective non-expert devices 3a,...,3N to determine a draft quality rating r?i and an associated level of confidence or "confidence value" of that draft quality rating. The method includes repeatedly receiving indications of quality from further of the non-expert devices and updating the draft quality rating and its associated level of confidence until the associated level of confidence meets a required confidence level. Once the required confidence level has been met the rating generator assembly sets the quality rating to the draft quality rating having the associated level of confidence meeting the required confidence level.
G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling
G09B 7/02 - Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by the student
100.
METHOD AND SYSTEM FOR PROCESSING ELECTRONIC RESOURCES TO DETERMINE QUALITY
QMM q11 qMM dijij cijij ,q11 UN N =u11 ,…,uNN rˆii and an associated level of confidence or "confidence value" of that draft quality rating. The method includes repeatedly receiving indications of quality from further of the non-expert devices and updating the draft quality rating and its associated level of confidence until the associated level of confidence meets a required confidence level. Once the required confidence level has been met the rating generator assembly sets the quality rating to the draft quality rating having the associated level of confidence meeting the required confidence level.
G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling
G06F 17/18 - Complex mathematical operations for evaluating statistical data
G09B 7/02 - Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by the student
